{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:04:19Z","timestamp":1784070259007,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.urolonc.2024.10.017","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T23:40:11Z","timestamp":1731454811000},"page":"178-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-2815","authenticated-orcid":false,"given":"Takuto","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.10.017_bib0001","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1308\/rcsann.2021.0230","article-title":"Metachronous isolated inferior vena cava tumour thrombus in renal cell cancer: a rare aftermath","volume":"104","author":"Kumar","year":"2022","journal-title":"Ann R Coll Surg Engl"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0002","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.21873\/invivo.11698","article-title":"Presurgical pazopanib improves surgical outcomes for renal cell carcinoma with high-level IVC tumor thrombosis","volume":"33","author":"Okamura","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0003","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-022-01883-7","article-title":"A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)","volume":"127","author":"Stewart","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12894-024-01405-y","article-title":"Neoadjuvant stereotactic ablative body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumor thrombus: a prospective pilot study","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0005","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1259\/bjr\/17514226","article-title":"Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma","volume":"82","author":"May","year":"2009","journal-title":"Br J Radiol"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0006","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/j.clgc.2019.01.013","article-title":"Neoadjuvant sunitinib decreases inferior vena caval thrombus size and is associated with improved oncologic outcomes: a multicenter comparative analysis","volume":"17","author":"Field","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0007","unstructured":"European Association of Urology. (2024). EAU Guidelines on renal cell carcinoma. Retrieved from https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma\/. Accessed July 10, 2024."},{"key":"10.1016\/j.urolonc.2024.10.017_bib0008","series-title":"NCCN clinical practice guidelines in oncology: kidney cancer","year":"2024"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0009","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CAD.0000000000000627","article-title":"Presurgical pazopanib for renal cell carcinoma with inferior vena caval thrombus: a single-institution study","volume":"29","author":"Terakawa","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2023.04.010","article-title":"The efficacy of presurgical therapy with avelumab and axitinib for renal cell carcinoma with inferior vena cava tumor thrombus","volume":"21","author":"Tobe","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2004.04897.x","article-title":"The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus","volume":"94","author":"Blute","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0012","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clgc.2020.10.007","article-title":"Modified Glasgow Prognostic Score as a predictor of prognosis in metastatic renal cell carcinoma treated with nivolumab","volume":"19","author":"Fujiwara","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3892\/ol.2024.14295","article-title":"Effects of neoadjuvant VEGF-TKI treatment on surgery for renal cell carcinoma: A systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00262-023-03621-1","article-title":"Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data","volume":"73","author":"Yanagisawa","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2006.02.065","article-title":"Surgical care, morbidity, mortality and follow-up after nephrectomy for renal cancer with extension of tumor thrombus into the inferior vena cava: retrospective study since 1990s","volume":"50","author":"Rigaud","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ol.2017.6131","article-title":"Presurgical neoadjuvant targeted molecular therapy for kidney cancer with concomitant vena cava tumor embolus: a clinical study","volume":"14","author":"Guo","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0017","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/s41416-023-02166-5","article-title":"The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma","volume":"128","author":"Mittal","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0018","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/KCA-170016","article-title":"Surgical complications of presurgical systemic therapy for renal cell carcinoma: a systematic review","volume":"1","author":"McCormick","year":"2017","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0019","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jamaoncol.2016.1197","article-title":"Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer","volume":"2","author":"Powles","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euros.2023.01.016","article-title":"Cytoreductive nephrectomy following immune checkpoint inhibitor therapy is safe and facilitates treatment-free intervals","volume":"50","author":"Shapiro","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0021","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0022","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.juro.2011.07.034","article-title":"External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology","volume":"186","author":"Pichler","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0023","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/iju.14648","article-title":"Predictors of postoperative recurrence in patients with non-metastatic pT3a renal cell carcinoma","volume":"28","author":"Ohsugi","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0024","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/cancers15082212","article-title":"Inflammatory networks in renal cell carcinoma","volume":"15","author":"Kruk","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0025","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/1759-7714.13903","article-title":"Is major pathologic response sufficient to predict survival in resectablenonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?","volume":"12","author":"Cai","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0026","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.2217\/fon-2019-0111","article-title":"A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)","volume":"15","author":"Bex","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0027","doi-asserted-by":"crossref","first-page":"12301","DOI":"10.2147\/OTT.S174149","article-title":"Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date","volume":"13","author":"Tacconi","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2024.10.017_bib0028","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T23:39:09Z","timestamp":1744414749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1078143924006938"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}